IE48372B1 - Therapeutically active imidazolylmethyl-substituted dibenzyl ethers - Google Patents
Therapeutically active imidazolylmethyl-substituted dibenzyl ethersInfo
- Publication number
- IE48372B1 IE48372B1 IE958/79A IE95879A IE48372B1 IE 48372 B1 IE48372 B1 IE 48372B1 IE 958/79 A IE958/79 A IE 958/79A IE 95879 A IE95879 A IE 95879A IE 48372 B1 IE48372 B1 IE 48372B1
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- acid addition
- addition salt
- solvent
- phenylthio
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Novel compounds I and their acid addition salts in which R is phenyl or phenylthio show activity against some fungi, yeasts and gram positive aerobic and anaerobic bacteria. The new compounds can be prepared by condensing 1-(2',4'- dichlorophenyl)-2-(N-imidazolyl- methyl)-ethanol with 4-chloromethyl- biphenyl, 4-bromomethyl-biphenyl, 1- phenylthio-4-chloromethyl-benzene or 1-phenylthio-4-bromomethyl-benzene in a solvent, most preferably dimethylsulphoxide.
Description
DESCRIPTION The invention relates to imidazolyImethy1-substituted dibenzyl ethers, to methods for their preparation and to pharmaceutical compositions containing them.
The invention provides compounds of the general formula I wherein R represents a phenyl or phenylthio group, that is 2,4-dichloro-4 uphenyl-a-(N-imidazolylmethyl)dibenzyl ether and 2,4-dichloro-4,-phenylthio-a-(N-imidazolyl-methyl)-dibenzyl ether, and pharmaceutically acceptable acid addition salts thereof.
Preferred pharmaceutically acceptable acid addition salts of the compounds I include those formed from both mineral and organic acids, such as hydrochloric, nitric, sulphuric, phosphoric, methane-sulphonic, succinic, maleic, fumaric, citric and tartaric acids. These salts may be prepared by conventional methods, for example by adding 48373 to the base in equimolecular amount the desired acid and then crystallizing the salt so obtained from a suitable solvent.
The compounds I and their salts are of interest for the activity they show against some fungi, yeasts and gram positive aerobic and anaerobic bacteria. The activity is coupled with a low toxicity. The compounds of the invention have been compared with two well-know antimycoticproducts, clotrimazole, i.e. C(imidazol-l-yl)-2-(o-chlorophenyl)-2,2-diphenylmethane 1 and miconazole.
Particularly interesting was the comparison between the activity and toxicity of the compounds I and of miconazole, wh^ch is 2,2',4,4'-tetrachloro-α-(N-imidazolyImethyl)-dibenzyl ether. In miconazole both benzyl groups are substitiuted in the 2- and 4-positions by chlorine atoms, whereas in the compounds I the benzyl group, which is α-unsubstituted is substituted in the 4-position by a phenyl or phenylthio group. This difference involves a notable reduction of toxicity which, for the new products, is from 3 to 4 times lower than that of miconazole, whereas the antifungal and antibacterial activity is about the same. The compounds according to the invention can be conveniently employed in human therapy for the local treatment of dermatosis, such as trichophytosis and candidosis, and further infections caused by fungi staphylococci and streptoccci. The compounds according to the invention may be admixed with pharmaceutically acceptable diluents or carriers to form pharmaceutical compositions, which may be in any suitable form, for example powders, ointments, creams, suspensions and dispersions.
The results obtained in biological assays are reported in Tables I, XI and III.
In Table I are reported the acute toxicity values (ΕΟ,-θ) of the compounds I and of both the comparison substances.
XO Toxicity, given in mg/Kg, has been evaluated per os in the mouse by conventional methods.
In Table II are reported the minimal inhibitory concentrations (MIC) of the cotpounds I and of both the cottparision substances. For MIC, the minimal concentration is intended, to be able bo inhibit the growth X5 of several fungi and yeasts. The MIC values have been determined according to the usual two-fold serial broth dilution technique.
The MIC values of the products under examination and of both comparison substances, referred to a certain number of gram positive bacteria and determined 2o according to the conventional two-fold serial broth dilution technique, are reported in Table III.
Experimental conditions were as follows: For Fungi Medium: Sabouraud liguid pH 5.7, (5 ml per tube) Inoculum: A ten days agar culture was washed with a physiological solution containing 10% Tween 80 (Tween" is a Trade Mark), then filtered through gauze and again suspended in physiological solution until the solution showed on a Coleman Jr II spectrophotometer, at a wavelength of 650 nm, a 50% transparence (T) (0.1 ml of spore suspension per ml). For Aspergillus niger, after filtration, a 1/10 dilution in physiological solution was prepared. 0.1 ml of this dilution constituted the inoculum for 5 ml. Temperature and incubation time: 25°C for 7 days.
For Yeasts Medium: Sabouraud liquid 5.7 (5 ml per tube) Inoculm: Yeasts were grown in Sabouraud liquid for 24 hours (Cryptococcus neoformans for 2 days). Cells were collected by centrifugation at 6500 rpm and again suspended in physiological solution so as to have a suspension giving on a Coleman Jr II spectrophotometer, at a wavelength of 650 nm, a 50% transparence (T). 0.1 ml of this suspension constituted the inoculum for 5 ml. Temperature and incubation time: 37°C for 48 hours.
For Gram Positive Bacteria Medium: Tryptic soy broth pH 7.3. (5 ml per tube) Inoculum: The day before the test, the microorganisms to be tested were transplanted in their respective media. After 18 hours incubation at 37°C, 0.1 ml of a 1:100 diluted suspension of each strain in broth, was inoculated in 5 ml of medium containing the products 4837 2 under examination at a serial concentration of from 0.009 to 160 mcg/ml.
Temperature and incubation time: 37°C for 18 hours.
TABLE I Acute toxicity (LD 50) per OS tn the mouse In mg/kg.
Formula I I : R=CgHj Formula I I: R=CgH5S Miconazole Clotrimazole 2400 3000 870 880 TABLE ti Antimycotic activity (MIC) in mcg/ml Phatogenous Agent Formula I ^C6H5 Formula I R= CgHgS Micanazole Clotrimazole C. Albicans R 5 40 5 10 C. Albicans QrUnenthal 5 40 5 10 C. Albicans 1040 10 80 20 40 C. Albicans 1041 20 80 20 40 C. Neolormans 0.312 0.156 0.078 0.625 T. Mentagroph. 2538 0.156 0.156 0.078 0.076 · T. Mentagroph. 10148 0.625 0.625 0.625 1.25 T. Mentagroph. 5865 1.25 1.25 0.31 0.62 T. Verrucosum 10 1.25 2.5 1.25 T. Rubrum 2121 . 0.625 0.625 0.312 1.25 M. Cants 28 20 2.5 5 2.5 A. Niger 20 10 40 10 P. Chrysogenum 20 5 20 40 E. Ploccosum 10 5 5 5 4837 3 TABLE III Antibacterial activity (MIC) in mcg/ml Phatogenous Agent Formula I R= C.H. 6 3 Formula I R = CgH5S Miconazole Clotrimazole S.aureus SG 511 0.039 0.039 0.312 0.312 S.aureus 10 B 0.039 0.018 0.312 1.25 Str.hemolyt 8 21 0.156 0.156 1.25 2.5 B. subtilis 0.156 0.078 0.625 2.5 Cl.novyi <1.25 5.0 <1.25 >160 Str.hemolyt 203 0.312 0.078 0.625 5 8 3 72 The invention further provides a method for the preparation of compounds of the general formula I as hereinbefore defined, the method comprising condensing in a solvent 1-(21,4'-dichlorophenyl)-2-(N-imidazolyl)-ethanol with a halobenzyl compound of the general formula V R· wherein R has the meaning previously ascribed to it and X represents chlorine or bromine atom.
As solvent, aromatic hydrocarbon, dimethylformamide, tetrahydrofuran, hexamethylphosphoramide and/or a mixture thereof can be employed, but it has been verified that condensation is more complete if dimethylsulphoxide is used. This leads to a higher yield and to a purer product. In this case it is not necessary to submit the base obtained from condensation to a purification through chromatographic column, whereas said purification is necessary using as solvents dimethylformamide or hexamethylphosphoramide. A simple filtration of the base solution through a silica gel column is in fact able to retain the small amounts of impurities. For the compound I, in which R represents a phenyl group, not even the filtration is necessary, and - 10 crystallization of the nitrate leads to a product sufficiently pure for pharmaceutical purposes. With the aprotic solvents specified above, there is usually used an alkali metal hydride or amide, which is able to salify the hydroxy group of the ethanol derivative.
Alternatively the condensation solvent may be an aliphatic alcohol having from 3 to 6 carbon atoms, such as t-butanol, and in this case the alkali metal hydride or amide should be replaced by an alkali metal alkanolate, for example potassium t-butoxide.
Afurther very useful expedient is to add small amounts of potassium iodide as catalyst before adding the halobenzyl derivative.
The condensation is suitably carried out at a temperature of from 20 °C to 100°C, over a period of from 6 to 36 hours The 1-(21, 4'-dichlorophenyl)-2-(N-imidazolyl)-ethanol may be prepared from l-chloroacetyl-2,4-dichlorobenzene (Beilstein-Handbuch der Org. Chem. IV° ed.vol.7, page 28) by reduction of the keto group using sodium borohydride and condensation with imidazole. The reduction and condensation can be effected in either order. The reduction may be effected in methanol and the condensation may be effected in dimethylformamide and methanol in the presence of sodium. The halobenzyl compounds of the general formula V are known. The preparation of 4-chloromethyl-biphenyl is described in Chem. Ber 66B, 1471,1933 and the preparation of l-bromomethyl-4-phenylthiobenzene is described in United States Patents Specification No. 3242193.
Examples 1 to 4, which follow, illustrate the invention while Examples A and B describe the preparation of the starting materials used in Examples 1 to 4.
EXAMPLE A 1-(2',4'-dichlorophenyl)-2-chloroethanol 49.5 g of sodium borohydride were added slowly and in small parts to suspension of 233 g of 1-(11-hydroxy-2'-chloroethyl)-2,4-dichlorobenzene in 1 litre of methanol stirred at room temperature. The solution thus obtained was stirred at room temperature for a further two hours, and it was then poured into 1 litre of 5N hydrochloric acid cooled with ice. After extraction with ethyl acetate or chloroform, the extract was washed with water, with IN sodium hydroxide, then again with water until neutrality, and finally with a saturated sodium chloride solution. The extract was dried, the solvent evaporated off and 220 g of an oil were obtained. The oil solidifed on standing and the solid melted at 48-51°C.
C% H% Analysis for C H Cl 0 8 7 3 Calculated Found 42.61 3.13 42.75 3.19 Cl% 47.17 47.43 8 3 7 2 - 12 example β 1- (2' , 41 -dichlorophenyl) -2- (N-imidazolyl) -ethanol 30g of sodium were added to a solution of 88.5 g of imidazole in 600 ml of methanol; the solvent was then evaporated off. The residue was dissolved in 300 ml of dimethylformamide and heated to 115-120°C. To the solution so obtained was added, dropwise and under stirring, a solution of 225 g of 1-(21,4'-dichlorophenyl) -2-chloroethanol in 400 ml of dimethylformamide. The mixture was heated to 115-120°C and maintained at that temperature for 20 minutes and, after subsequent cooling to 40°C, 2500 ml of iced water were added under vigorous stirring. The product precipitated under stirring over a period of about two hours, the upper liquid was then decanted off, a further 2500 ml of water were added and, after standing, the whole was filtered. The precipitate thus obtained was dried and crystallized from toluene. 170 g of the desired product, melting at 134-135°C, was obtained.
Analysis for CjjHggClgNjO C% H% N% Cl% Calculated 51.38 3.92 10.89 27.58 Found 51.62 3.80 10.73 27.76 EXAMPLE 1 2,4-Dlchloro-41-phenylthio-a-7(N-lmidazolylmethyl)-dibenzyl ether (X: R=CgHgS) - 13 METHOD I A solution of 2.57 g of l-(2',4,-dichlorphenyl)-2-(N-imidazolyl)-ethanol, prepared as described in Example B, in 10 ml of hexamethylphosphoramide was dropped at 25°C into a suspension of 0.52 g of sodium hydride (50% in oil) in 5 ml of hexamethylphosphoramide. When hydrogen emission was over, the salification was completed by heating for 1 hour at 50°C. After cooling to 25°C, 2.58 g of l-chloromethyl-4-phenylthiobenzene were added. The temperature was raised to 50°C and maintained at that temperature for 12 hours. At the end of the reaction, the mixture was poured into 200 ml of water, the product was extracted with diethyl ether, the solvent was evaporated off and the residue was purified twice on a silica gel column, using ethyl acetate as eluant and testing the various fractions by TLC. The solvent was evaporated off the middle fractions to give 2.4 g of the desired base as a yellowish oil, showing a single spot on TLC.
Analysis for £24^0^^2°5 C% H% N% Cl% S% Calculated 63.30 4.44 6.13 15.57 7.04 Found 63.86 4.24 6.41 15.29 6.97 METHOD II 0.66 g of sodium hydride (50% in oil) were added at «β 4 8 3 7 2 2O-3O°C and under nitrogen atmosphere to 3.86 g of l-(2',4'-dichlorophenyl)-2-(N-imidazolyl)-ethanol in 15 ml of dimethylsulphoxide (dried on calcium hydride).
The mixture was heated under stirring at 5O-6O°C until 5 gas emission was over. After cooling to 2O-25°C, 0.5 g of potassium iodide were added and slowly a solution of 3.51 g of l-chloromethyl-4-phenylthiobenzene in 4 ml of dimethylsulphoxide was dropped in. The mixture was stirred at 2O-25°C until addition of the 1-chloro10 methyl-4-phenylthiobenzene was over. The mixture was then poured into 150 ml of water and extracted with diethyl ether. To the ethereal solution, after drying on anhydrous sodium sulphate, was added excess 4N nitric acid solution in diethyl ether: the desired product precipitated as nitrate, an oil which solidified on standing. After standing for 20 hours, the ethereal liquid was decanted off and the residue was crystallized from ethanol. The nitrate thus obtained, not completely pure, was dissolved in water and excess sodium carbonate was added in order to liberate the base which was then extracted with ethyl acetate. The base, obtained by filtration, was purified on a silica gel column using ethyl acetate as eluant. The combined fractions containing the desired product were evaporated to dryness. The residue was dissolved in diethyl ether, again transformed intothe nitrate and crystallized from ethanol.
Yield: 3.1 g of a white crystalline powder, melting at 134°C.
Analysis for c24H2ON2Cl20S’HN03 C% H% N% Cl% S% Calculated 55.61 4.08 8.11 13.68 6.18 Found 55.32 4.08 8.16 13.56 6.32 EXAMPLE 2 2,4-Dichloro-4'-phenyl-α-(H-imidazolyImethyl)-dibenzyl ather (X: R=C6H5) METHOD I A mixture consiting of 2.02 g of potassium t-butoxide in 30 ml of t-butanol was prepared at 2O-25°C and in nitrogen atmosphere. 3.86 g of 1-(21,4'-dichlorophenyl)-2-(N-imidazolyl)-ethanol, prepared according to Example B, were added. The solution was refluxed for 1 hour and then cooled to 20-25°C. 3.03 g of 4-chloromethylbiphenyl were added, and the solution was again refluxed for 5 hours. After cooling to 2O-25°C the whole was poured into water and the base extracted with ethyl acetate.
The extract was washed with water and the solvent evaporated off. The residue was dissolved in diethyl ether (80 ml) and left to stand overnight. The insoluble substances were filtered off and the filtrate was - 16 treated with nitric acid dissolved in diethylether.
An oil, which solidifed on standing, was obtained.
The residue consisting of 2,4-dichloro-4'-phenyl-&-(N-imidazolymethyl)-dibenzyl ether nitrate, was crystallized from ethanol or ethyl acetate. A product (4.3 g), shown to be pure on TLC and melting 14O-141°C, was obtained.
Analysis for C2 ^20^2^2^ ‘ CS HS NS CIS 10 Calculated 59.25 4.35 8.64 14.57 Found 59.17 4.14 8.61 14.46 METHOD I (a) To a solution of 0.37 g of sodium metal in 20 ml or n-propanol, 4.1 g of 1- (2',4'-dichlorophenyl)-2-(N15 -midazolyl)-ethanol were added and the mixture was refluxed for two hours under stirring. After cooling to room temperature, 0.5 g of potassium iodide and 3.25 g of 4-chloromethylbiphenyl were added under stirring and the mixture was again refluxed. At the end of the reaction, the mixture was filtered off and washed with ethanol. The filtrate was evaporated to dryness and the residue dissolved in diethyl ether. The insoluble residue was filtered off and the clear ethereal solution thus obtained was treated with a mixture of nitric acid and diethyl ether. The 2,4-dichloro-4'-phenyl-α-(N48372 -imidazolyImethyl)-dibenzyl ether nitrate so formed was crystallized from ethanol. A product (2.1 g) having the same characteristics as that prepared according to the previous method and showing a single spot on TLC was obtained.
METHOD II 0.66 g of sodium hydride were added, under nitrogen atmosphere and at 20-25°C, to a solution of 3.86 g of l-(2',4'-dichlorophenyl)-2-(N-imidazolyl)-ethanol in 15 ml of dimethylsulphoxide (dried on calcium hydride).
The mixture was heated at 50-60°C until gas emission was over, The mixture was then cooled to 2O-25°C, 0.5 g of potassium iodide were added and a solution of 3.03 g of 4-chloromethylbiphenyl in 7 ml of dimethylsulphoxide (dried on calcium hydride) was dropped in. The whole was stirred for about 20 hours at 2O-25°C and then poured into water. The product was extracted with ethyl acetate and then treated as described in Method I. Yield 4.6 g.
EXAMPLE 3 Salts of 2,4-dichloro-4'-phenylthio-a-(N-imidazolylmethyl)-dibenzyl ether were prepared by reacting the free base, dissolved in ethanol, with an alcohol solution of the desired acid and subsequently crystallizing the salt so obtained from a suitable solvent. The free base was 8 3 7 2 - 18 prepared according to Example 1, Method I, or by liberation from its nitrate, prepared according to Method II, by treatment with sodium carbonate, extraction with diethyl ether and evaporation.
InTable IV the solvents of crystallization, the elemental analysis and the melting points of some salts are reported.
In Table V are listed the same data for some salts of 2,4-dichloro-4'-phenyl-α-(N-imidazolyImethyl)-dibenzyl ether, obtained using the methods described above.
* W ε © V» O> © x © ? o V I i6s 1 y s CM fe n © 8 ϋ cm Cm CM >· T* V" cm Found y & h. K. © K 9 Cm z © x’ X* © *· co x © CM ? © X V x’ x x’ y CM X r· © V CM 9 s o s' s' s' S © y © © w © a ε w cd © v- ©‘ © T- *- y CM >· X s © <0 V- © u V CM CM cm’ CM i ce y o s 8 9 R 8 z © © © o y © co R 8 s Oi X x’ x < x‘ X* y © © © © X s 8 s' s s' 8 8 o o o 0 0 CL © © © *- © © Sm X X 7 1 I T 1 r· © K T" v R 4* fe «0 X g ®s i if e ΐ O o F fi | fi fi »> £ ω UJ £ UJ £ w t ΐ I 1 • « • c 3 ti if 5 5 3 9> ii Έ 5 Is • « # I * 9i R © Λ CO © y © 9 IO rv © © © ϋ R CO CO CM Found y ζ I ί 5.M 5.25 © w 4,54 © xr * o © s o> CM © b. x ζ Χ* <0 x x’ x’ y © X 8 g *" CD fe ϋ cm’ © 35 CM © CO © s' ν m s V) cd © y co © © X R CM © ϋ R co V» <0 CM *- ♦» 1 β y 8 fe 0) T~ CO © s 8 ζ © 10 © x’ X Ο y D CO 10 CM 9 So s I x X* x x’ X y 8 R © co R © © Ο CM © S' CM © X © s' o ϋ o ct CM • © R w C 0 ζ 1 T vj· 7 s K CM K R ·* © T" 8 *« • £ 1= > « < i I I £ i £ fr w UJ Ul UJ UJ « ί • 5 i 1 « £ $ f « 3 n H • t. o - 20 EXAMPLE 4 Pharmaceutical antifungal and anitbacterial formulations, comprising active compounds according to the invention at concentrations of from 0.5 to 5% by weight, preferably from 1 to 3% by weight, in admixture with pharmaceutically acceptable diluents or carriers, were prepared. Examples of the composition of an ointment, a powder, a glycolic solution and a gel are given below.
Ointment 2,4-dichloro-4'-phenylthio-α-(N-imidazolylmethyl)dibenzyl ether nitrate 2 g Lanolin 20 g Vaseline q.s. to 100 g Vaselineis a Trade Mark Glycolic solution 2,4-dichloro-4'-phenylthio-α-(N-imidazolylmethyl)dibenzyl ether nitrate 2 g Propylene Glycol q.s. to 100 ml Powder 2,4-dichloro-4'-phenylthio-α-(N-imidazolylmethyl)dibenzyl ether nitrate 2 g Lanolin 1.5 g Soybean lecithin 2 g Talc q.s. to 100 g - 21 Gel 2,4-dichloro-4'-phenylthio-o-(N-imidazolyImethyl)dibenzyl ether nitrate 2 g Carbopol 2 g Water 2 g Polyethylene glycol q.s. to 100 g Triethanolamine q.s. to about pH 3 Carbopol is a Trade Mark.
Claims (10)
1.
2. ,4-Dichloro-4'-phenylthio-α-(N-imidazolyImethyl)-dibenzyl ether or a pharmaceutically acceptable acid addition salt thereof.
3. An acid addition salt according to claim 1, being a hydrochloride, nitrate, maleate, methanesulphonate, 10 p-toluenesulphonate or phosphate.
4. An acid addition salt according to claim 2, being a hydrochloride, nitrate, sulphate, a maleate, p-toluenesulphonate or citrate.
5. A process for the preparation of a compound of the wherein R represents phenyl or phenylthio group, the process comprising condensing 1-(2 1 ,4'-dichlorophenyl)-2-(N-imidazolyImethyl)-ethanol with a halobenzyl - 23 derivative of the general formula V as herein defined in a solvent. 5 2. 2,4-Dichloro-4'-phenyl-a-(N-imidazolyImethyl)-dibenzyl ether or a pharmaceutically acceptable acid addition salt thereof.
6. A process according to claim 5 in which the solvent is an aromatic hydrocarbon, dimethylformamide, tetrahydrofuran, hexamethylphosphoramide or dimethyl sulphoxide and the condensation is carried out in the presence of an alkali metal hydride or amide.
7. A process according to claim 5 in which the solvent is an aliphatic alcohol having from 3 to 6 carbon atoms and the reaction is carried out in the presence of an alkali metal alkanolate.
8. A process according to any of claims 5 to 7 carried out in the presence of potassium iodide as catalyst.
9. A process according to any of claims 5 to 8 carried out at a temperature of from 20 to 100°C for from 6 to 36 hours. 10. A pharmaceutical composition comprising a compound according to any to claims 1 to 4 in admixture with a pharmaceutically acceptable diluent or carrier. 11. A pharmaceutical composition according to claim 10 in which the compound according to any of claims 3 to 4 is present in an amount of from 0.5 to 5% by weight. 12. A pharmaceutical composition according to claim 10 or claim 11 being an ointment, a powder, a glycolic solution or a gel. 13. A pharmaceutical composition substantially as 5 described herein with reference tb Example 4. 14. A process for the preparation of a compound of the general formula 1 or an acid addition salt of such a compound, substantially as herein described with reference to any of Examples 1 to 3.
10. 15. A compound of formula 1 when prepared by a process according to any of claims 5 to 9 and 14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT23546/78A IT1096361B (en) | 1978-05-18 | 1978-05-18 | THERAPEUTICALLY ACTIVE REPLACED BONDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE790958L IE790958L (en) | 1979-11-18 |
| IE48372B1 true IE48372B1 (en) | 1984-12-26 |
Family
ID=11208025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE958/79A IE48372B1 (en) | 1978-05-18 | 1979-08-08 | Therapeutically active imidazolylmethyl-substituted dibenzyl ethers |
Country Status (29)
| Country | Link |
|---|---|
| JP (1) | JPS605592B2 (en) |
| AR (1) | AR219596A1 (en) |
| AT (1) | AT372950B (en) |
| AU (1) | AU523053B2 (en) |
| CA (1) | CA1115718A (en) |
| CH (1) | CH639075A5 (en) |
| DD (1) | DD143608A5 (en) |
| DE (1) | DE2917244C2 (en) |
| DK (1) | DK153838C (en) |
| EG (1) | EG14345A (en) |
| ES (1) | ES480552A1 (en) |
| FI (1) | FI71309C (en) |
| FR (1) | FR2426047A1 (en) |
| GB (1) | GB2025395B (en) |
| GR (1) | GR68396B (en) |
| HU (1) | HU182565B (en) |
| IE (1) | IE48372B1 (en) |
| IL (1) | IL57245A (en) |
| IT (1) | IT1096361B (en) |
| MX (1) | MX5927E (en) |
| NL (2) | NL189255C (en) |
| NO (1) | NO152840C (en) |
| NZ (1) | NZ190412A (en) |
| PH (1) | PH14782A (en) |
| PT (1) | PT69537A (en) |
| SE (1) | SE444812B (en) |
| SU (1) | SU816399A3 (en) |
| YU (1) | YU112279A (en) |
| ZA (1) | ZA792015B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1155853A (en) * | 1980-06-06 | 1983-10-25 | Joseph A. Martin | Imidazole derivatives and preparation thereof |
| FR2541114B1 (en) * | 1983-02-23 | 1986-04-11 | Sanofi Sa | ANTIFUNGAL PHARMACEUTICAL COMPOSITIONS FOR ORAL USE CONTAINING OMOCONAZOLE |
| DK79184A (en) * | 1983-02-23 | 1984-08-24 | Sanofi Sa | FUNGICIDE PHARMACEUTICAL AGENTS CONTAINING AN IMIDAZOLD DERIVATIVE |
| CA1250586A (en) * | 1984-02-02 | 1989-02-28 | Manuel Raga | 1h-imidazole derivatives and process for their production |
| DE3413365A1 (en) * | 1984-04-09 | 1985-12-19 | Merz + Co GmbH & Co, 6000 Frankfurt | SUBSTITUTED PHENYLETHYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS |
| IT1200422B (en) * | 1985-03-19 | 1989-01-18 | Ripari Gero Ist Farm Biolog | COMPOUND WITH ANTIMICROBIA ACTIVITY, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT |
| ES2249992B1 (en) | 2004-09-13 | 2007-03-01 | Ferrer Internacional, S.A. | A PROCEDURE FOR MANUFACTURING ENANTIOMERIC COMPOUNDS OF IMIDAZOL. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU557755A3 (en) * | 1968-08-19 | 1977-05-05 | Янссен Фармасьютика Н.В. (Фирма) | Method for preparing imidazole derivatives |
| GB1475271A (en) * | 1975-04-30 | 1977-06-01 | Pfizer Ltd | 1-aryl-2-1-imidazolyl-alkyl ethers and thioethers and their use as antifungal agents |
-
1978
- 1978-05-18 IT IT23546/78A patent/IT1096361B/en active Protection Beyond IP Right Term
-
1979
- 1979-04-24 PT PT69537A patent/PT69537A/en unknown
- 1979-04-26 ZA ZA792015A patent/ZA792015B/en unknown
- 1979-04-27 DE DE2917244A patent/DE2917244C2/en not_active Expired
- 1979-04-29 EG EG250/79A patent/EG14345A/en active
- 1979-05-07 AR AR276430A patent/AR219596A1/en active
- 1979-05-07 GR GR59034A patent/GR68396B/el unknown
- 1979-05-07 HU HU79RE645A patent/HU182565B/en unknown
- 1979-05-09 AT AT0345079A patent/AT372950B/en not_active IP Right Cessation
- 1979-05-10 NZ NZ190412A patent/NZ190412A/en unknown
- 1979-05-10 PH PH22475A patent/PH14782A/en unknown
- 1979-05-10 IL IL57245A patent/IL57245A/en unknown
- 1979-05-11 CA CA327,426A patent/CA1115718A/en not_active Expired
- 1979-05-14 GB GB7916670A patent/GB2025395B/en not_active Expired
- 1979-05-14 NO NO791599A patent/NO152840C/en unknown
- 1979-05-14 DD DD79212866A patent/DD143608A5/en unknown
- 1979-05-14 ES ES480552A patent/ES480552A1/en not_active Expired
- 1979-05-14 DK DK196579A patent/DK153838C/en not_active IP Right Cessation
- 1979-05-14 YU YU01122/79A patent/YU112279A/en unknown
- 1979-05-15 FI FI791543A patent/FI71309C/en not_active IP Right Cessation
- 1979-05-16 NL NLAANVRAGE7903872,A patent/NL189255C/en not_active IP Right Cessation
- 1979-05-16 JP JP54060971A patent/JPS605592B2/en not_active Expired
- 1979-05-16 CH CH456979A patent/CH639075A5/en not_active IP Right Cessation
- 1979-05-17 AU AU47149/79A patent/AU523053B2/en not_active Expired
- 1979-05-17 FR FR7912638A patent/FR2426047A1/en active Granted
- 1979-05-17 SE SE7904319A patent/SE444812B/en not_active IP Right Cessation
- 1979-05-17 SU SU792771698A patent/SU816399A3/en active
- 1979-05-18 MX MX797989U patent/MX5927E/en unknown
- 1979-08-08 IE IE958/79A patent/IE48372B1/en not_active IP Right Cessation
-
1993
- 1993-02-19 NL NL930014C patent/NL930014I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4328348A (en) | Novel benzylimidazole derivatives | |
| DE3007006C2 (en) | Quinolonecarboxylic acid derivatives, their salts, processes for their preparation and agents containing these derivatives | |
| JPS5823671A (en) | Manufacture of imidazolyl-o,n-acetal and salt | |
| US4128639A (en) | Nitrosourea analogs of thymidine | |
| EP0080818B1 (en) | Erythromycin b derivatives | |
| US4145542A (en) | 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives | |
| JPS59155381A (en) | Benzoquinolizinecarboxylic acid derivative and its preparation | |
| IE48372B1 (en) | Therapeutically active imidazolylmethyl-substituted dibenzyl ethers | |
| US4221803A (en) | Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections | |
| EP0028698B1 (en) | Quinoline compounds, process for their preparation, and pharmaceutical compositions | |
| EP0080819A1 (en) | 11-0-Alkylerythromycin A derivatives | |
| DD263289A5 (en) | METHOD FOR PRODUCING DISUBSTITUTED PIPERAZINE | |
| HU193916B (en) | Process for preparing substituted imidazole derivatives and pharmaceutics comprising these compounds | |
| JPH02131483A (en) | Benzoheterocyclic compound | |
| DE2322576A1 (en) | ANTIBIOTIC DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | |
| DE68915928T2 (en) | Benzoheterocyclic compounds. | |
| PL164879B1 (en) | Method for the production of new PL triazolylhydrazide derivatives | |
| EP0227011A2 (en) | Imidazole derivatives | |
| US4141968A (en) | Novel salts of 1,3-bis-(β-ethylhexyl)-5-amino-5-methyl-hexahydropyrimidine in compositions having bacteriostatic activity | |
| KR820002099B1 (en) | Process for preparing substituted dibenzyl ehters | |
| US4142050A (en) | Salts of 1,3-bis(β-ethylhexyl)-5-amino-5-methyl-hexahydropyrimidine | |
| DE2257542A1 (en) | 3,6-BIS- (2-PIPERIDINYL) -2,5-PIPERAZINDIONE | |
| FI85271C (en) | FREEZING FOR PYRIDOYL-IMIDAZOLE-2-ONER. | |
| DD143910A5 (en) | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDINES | |
| US4207320A (en) | Amino-substituted imidazo[1,2-a:3,4-a']diquinolin-15-ium salts compositions and method of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Request for grant of supplementary protection certificate |
Free format text: SPC 63/93:19930629 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: SPC 63/93 EXPIRES:20001013 |
|
| MK9A | Patent expired |